Nippon Tungsten Co., Ltd. (6998)

Overview

Genor Biopharma Holdings Limited is a biopharmaceutical company engaged in the development and commercialization of oncology and autoimmune drugs for the global market. With its headquarters in Shanghai, China, the company has established a significant presence both within the country and on the international stage. Originally founded in 2007 as JHBP (CY) Holdings Limited, it underwent a rebranding to Genor Biopharma Holdings Limited in June 2021. The organization's strategic focus is on leveraging cutting-edge science to address unmet medical needs in oncology and autoimmune diseases, positioning it as a key player in the biopharmaceutical industry.

Products and Services

• GB242: A biosimilar to infliximab (Remicade), GB242 is designed for treating various autoimmune disorders, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, and several forms of colitis and Crohn's disease. This candidate reflects the company's commitment to providing accessible alternatives to established autoimmune therapies.

• GB491 (lerociclib): As an oral CDK4/6 inhibitor, GB491 is primarily targeted at breast cancer treatment. Its development underscores Genor Biopharma's focus on catering to the needs of cancer patients with precision medicine that aims to halt the progression of the disease at a molecular level.

• GB492 and GB226: This combination is currently under a Phase 1/2 clinical trial for the treatment of solid tumors. This innovative approach, integrating a stimulator of interferon genes with another active agent, exemplifies the company's dedication to pushing the boundaries of cancer treatment.

• GB226: Positioned for various phases of clinical trials across different cancer types, GB226 represents a versatile therapeutic candidate. Its applications range from treating 2L+ cervical cancer in Phase III to addressing ASPS and r/r PMBCL in Phase II, along with trials for EGFR+ NSCLC and mCRC, showcasing the company's expansive oncology pipeline.

• GB261 and GB263T: These candidates are in Phase I/II trials focusing on treatments for NHL and NSCLC, respectively. Both drugs contribute to Genor Biopharma's targeted therapy strategy, aiming to harness specific mechanisms for fighting cancer.

• GB221: This Phase III drug candidate is aimed at treating HER2 + 1L/2L+ metastatic breast cancer, reflecting the company's effort in addressing this aggressive form of cancer with potentially ground-breaking therapeutics.

• GB223, GB241, and GB251: With various focuses, including GCTB, PMO, DLBCL, and HER2 + mBC, these candidates in Phase I and III trials, illustrate Genor Biopharma's diverse approach to combating cancer through a broad spectrum of targeted and innovative therapies.

• Pre-clinical candidates: GB262, GB264, GB266, GB267, and GB268: These are under pre-clinical trials primarily aimed at treating cancer, indicating Genor Biopharma's commitment to expanding its portfolio and exploring new horizons in oncology research and development.